Business Description
GenSight Biologics is a Paris-based biotechnology company focused on developing treatments for diseases that damage the retina and central nervous system. Its two most advanced treatments use gene therapy to address Leber hereditary optic neuropathy and retinitis pigmentosa, with additional early-stage work targeting other eye and brain conditions. The company draws on licensing partnerships with leading research institutions across Europe and the United States to support its work. Founded in 2012, GenSight continues to advance its pipeline toward bringing meaningful options to patients with limited or no current treatment choices.
